TuHURA Biosciences Inc HURA
News
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
These 16 stocks are a short seller's dream - likely losers no matter what the market does

